Advanced prostate cancer


ADT Androgen deprivation therapy
BMD Bone mineral density
CAB Combined androgen blockade
CAM Complementary and alternative therapies
CI Confidence interval (see Glossary)
CRPC Castration-resistant prostate cancer
CT Computed tomography
DES Diethylstilbestrol
DEXA Dual energy x-ray absorptionmetry
EBRT External beam radiotherapy
EORTC European Organisation for Research and Treatment of Cancer
GnRH Gonadotrophin releasing hormone
Gy A unit of absorbed radiation = to 1rad
HR Hormone resistant
IGRT Intensity modulated radiation treatment
IMRT Image guided radiation treatment
IV intra-venous
LHRH Luteinising hormone releasing hormone
M1 Evidence of metastatic disease
M0 No evidence of metastases
MRI Magnetic resonance imaging
MSCC Metastatic spinal cord compression
PBS Pharmaceutical Benefits Scheme – Australian Government
PET Positron emission tomography
PSA Prostate specific antigen
QCT Quantitative computerised tomography
QOL Quality of life
RANK Receptor activator of nuclear kappa B
RCT Randomised controlled trial
RR Relative risk
RTOG Radiation Therapy Oncology Group
SES Socioeconomic status
SRE Skeletal-related events
SWOG South Western Oncology Group
TROG Trans Tasman Radiation Oncology Group
TURP Trans-urethral resection of the prostate (see Glossary)
XRT X-ray therapy

Back to top